FDA Approves REYATAZÂ (atazanavir Sulfate) 300 Mg Single Capsule Formulation In Combination Therapy For Adults With HIV-1 Infection

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) enjoy granted permission of a tentative 300 mg lone tablet formulation of REYATAZ® (atazanavir sulfate) all for the revealing of HIV-1 infectivity within adults in place of part of a set of concurrence psychotherapy. Taken once each day along next to ritonavir and stores as part of a anti-HIV medication regimen, the REYATAZ 300 mg single capsule formulation can replace two REYATAZ 150 mg capsule for: patients who have beforehand received anti-HIV medicine, patients who will be acceptance tenofovir disoproxil fumarate, and patients who have never taken anti-HIV medicines that oblige SUSTIVA® (efavirenz) as part of their anti-HIV drug regimen. The REYATAZ single capsule formulation will be reachable in the United States within seven conglomerate days.

"Bristol-Myers Squibb be committed to helping organize the advancement and amount produced of ultramodern once-daily HIV medicines," said Anthony Hooper, president, U.S. Pharmaceuticals, Bristol-Myers Squibb Company. "With the REYATAZ 300 mg single capsule formulation approval, Bristol-Myers Squibb presently has one drug, once-daily HIV medication opportunity available in three drug classes, as part of combination therapy." REYATAZ is an anti-HIV drug that obstruct the action of the HIV protease enzyme, which is needed for the virus to multiply. REYATAZ is a prescription medicine previously owned in combination with other medicines to satisfaction populace who be festering with HIV. REYATAZ has be studied in 48-week trial in both patients who have taken or have never taken anti-HIV medicines. REYATAZ instigate not nurse subsidise to health HIV, a solemn ailment, or give a hand obstruct ratification of HIV to others. Since REYATAZ be first of all passed by possessions of the FDA in 2003, almost 129,000 patients in the United States have been treat with the drug. Bristol-Myers Squibb will keep trying to make the at this time available REYATAZ 200 mg, 150 mg, and 100 mg once-daily capsules.

pharmacy news online